Zacks Investment Research
03 Mar 2026, 18:00 UTC · 36w ago
Verdict
Source says Upgrade to Buy. We score ACRV +1.00 across two claims.
Score confirms the headline.
Upgrade to Buy
Rating stated in the headline
+1.00strongly bullish
More positive than 98% of ticker scores this week
Top 1 mover · tap to explore
What the story claims
2 claims · scored −1 bearish … +1 bullish
Acrivon Therapeutics, Inc. (ACRV) has been upgraded to a Zacks Rank #2 (Buy).
So whatA rating upgrade based on improving earnings estimates typically signals positive near-term price momentum for a specific equity.
More positive than 76% of claims this week
There has been an upward trend in earnings estimates for Acrivon Therapeutics, Inc.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company received a Zacks Rank #2 (Buy) upgrade due to an upward trend in earnings estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
+4.7%
Price agrees with the score
$1.60 vs $1.53 close before publication (Mar 2) · not market-adjusted
ACRV chart →
